LRRC15 (Leucinerich repeatcontaining protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFbeta on activated fibroblasts (alphaSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15positive stromal desmoplasia or cancers of mesenchymal origin. ABBV085 is a monomethyl auristatin E (MMAE)containing antibody-drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromalpositive/cancernegative, and LRRC15 cancerpositive models as a monotherapy, or in combination with standardofcare therapies. - Proteine/Peptide
Immobilized Samrotamab at 1 µg/mL (100 µL/well) can bind Biotinylated Cynomolgus / Rhesus macaque LRRC15 Protein, Fc,Avitag (Cat. No. LR5-C82F3) with a linear range of 0.1-6 ng/mL (QC tested).
Immobilized Biotinylated Cynomolgus / Rhesus macaque LRRC15 Protein, Fc,Avitag (Cat. No. LR5-C82F3) at 1 µg/mL (100 µL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 µg/well) plate can bind Samrotamab with a linear range of 0.1-3 ng/mL (Routinely tested).
Biotinylated Cynomolgus / Rhesus macaque LRRC15 Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
* VAT and and shipping costs not included. Errors and price changes excepted
